TY - JOUR
T1 - The C-terminal portion of the nucleocapsid protein demonstrates SARS-CoV antigenicity.
AU - Liu, Guozhen
AU - Hu, Shaohui
AU - Hu, Yongwu
AU - Chen, Peng
AU - Yin, Jianning
AU - Wen, Jie
AU - Wang, Jingqiang
AU - Lin, Liang
AU - Liu, Jinxiu
AU - You, B.
AU - Yin, Y.
AU - Li, Shuting
AU - Wang, Hao
AU - Ren, Yan
AU - Ji, Jia
AU - Zhao, Xiaoqian
AU - Sun, Yongqiao
AU - Zhang, Xiaowei
AU - Fang, Jianqiu
AU - Wang, Jian
AU - Liu, Siqi
AU - Yu, Jun
AU - Zhu, Heng
AU - Yang, Huanming
N1 - Funding Information:
We thank Ministry of Science and Technology of China, Chinese Academy of Sciences, and National Natural Science Foundation of China for financial supports. We are indebted to collaborators and clinicians from Institute of Microbiology and Epidemiology in Chinese Academy of Militarily Medical Sciences, Peking Union Medical College Hospital, National Center of Disease Control of China, and the Municipal Governments of Beijing and Hangzhou.
PY - 2003/8
Y1 - 2003/8
N2 - In order to develop clinical diagnostic tools for rapid detection of the SARS-CoV (severe acute respiratory syndrome-associated coronavirus) and to identify candidate proteins for vaccine development, the C-terminal portion of the nucleocapsid (NC) gene was amplified using RT-PCR from the SARS-CoV genome, cloned into a yeast expression vector (pEGH), and expressed as a glutathione S-transferase (GST) and Hisx6 double-tagged fusion protein under the control of an inducible promoter. Western analysis on the purified protein confirmed the expression and purification of the NC fusion proteins from yeast. To determine its antigenicity, the fusion protein was challenged with serum samples from SARS patients and normal controls. The NC fusion protein demonstrated high antigenicity with high specificity, and therefore, it should have great potential in designing clinical diagnostic tools and provide useful information for vaccine development.
AB - In order to develop clinical diagnostic tools for rapid detection of the SARS-CoV (severe acute respiratory syndrome-associated coronavirus) and to identify candidate proteins for vaccine development, the C-terminal portion of the nucleocapsid (NC) gene was amplified using RT-PCR from the SARS-CoV genome, cloned into a yeast expression vector (pEGH), and expressed as a glutathione S-transferase (GST) and Hisx6 double-tagged fusion protein under the control of an inducible promoter. Western analysis on the purified protein confirmed the expression and purification of the NC fusion proteins from yeast. To determine its antigenicity, the fusion protein was challenged with serum samples from SARS patients and normal controls. The NC fusion protein demonstrated high antigenicity with high specificity, and therefore, it should have great potential in designing clinical diagnostic tools and provide useful information for vaccine development.
UR - http://www.scopus.com/inward/record.url?scp=13744261436&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=13744261436&partnerID=8YFLogxK
U2 - 10.1016/S1672-0229(03)01024-6
DO - 10.1016/S1672-0229(03)01024-6
M3 - Article
C2 - 15629031
AN - SCOPUS:13744261436
SN - 1672-0229
VL - 1
SP - 193
EP - 197
JO - Genomics, proteomics & bioinformatics / Beijing Genomics Institute
JF - Genomics, proteomics & bioinformatics / Beijing Genomics Institute
IS - 3
ER -